COLLEGIUM PHARMACEUTICAL INC

NASDAQ: COLL (Collegium Pharmaceutical, Inc.)

Kemas kini terakhir: 4 hari lalu, 6:20PM

47.85

0.34 (0.72%)

Penutupan Terdahulu 47.51
Buka 47.51
Jumlah Dagangan 662,241
Purata Dagangan (3B) 462,982
Modal Pasaran 1,512,585,216
Harga / Pendapatan (P/E TTM) 29.36
Harga / Pendapatan (P/E Ke hadapan) 4.79
Harga / Jualan (P/S) 2.51
Harga / Buku (P/B) 5.51
Julat 52 Minggu
23.23 (-51%) — 48.37 (1%)
Margin Keuntungan 6.61%
Margin Operasi (TTM) 13.71%
EPS Cair (TTM) 1.22
Pertumbuhan Hasil Suku Tahunan (YOY) 22.70%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -91.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 411.94%
Nisbah Semasa (MRQ) 1.08
Aliran Tunai Operasi (OCF TTM) 198.44 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 341.32 M
Pulangan Atas Aset (ROA TTM) 7.95%
Pulangan Atas Ekuiti (ROE TTM) 19.23%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menaik Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menaik Bercampur
Stok Collegium Pharmaceutical, Inc. Menaik Menaik

AISkor Stockmoo

-0.1
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -3.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 4.0
Purata -0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
COLL 2 B - 29.36 5.51
RGC 6 B - - 1.22
ANIP 2 B - 53.03 3.63
AMPH 1 B - 12.26 1.58
DVAX 1 B - - 2.41
PCRX 1 B - 51.47 1.42

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 1.69%
% Dimiliki oleh Institusi 117.12%
Julat 52 Minggu
23.23 (-51%) — 48.37 (1%)
Julat Harga Sasaran
46.00 (-3%) — 48.00 (0%)
Tinggi 48.00 (Truist Securities, 0.31%) Beli
Median 46.00 (-3.87%)
Rendah 46.00 (Needham, -3.87%) Beli
46.00 (HC Wainwright & Co., -3.87%) Beli
Purata 46.67 (-2.47%)
Jumlah 3 Beli
Harga Purata @ Panggilan 40.00
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 07 Nov 2025 46.00 (-3.87%) Beli 42.30
Truist Securities 07 Nov 2025 48.00 (0.31%) Beli 42.30
Needham 28 Oct 2025 46.00 (-3.87%) Beli 35.41

Tiada data dalam julat masa ini.

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda